After Cantor Fitzgerald and Canaccord Genuity gave Intra-Cellular Therapies (NASDAQ: ITCI) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on Intra-Cellular Therapies yesterday and set a price target of $28. The company’s shares closed yesterday at $21.84.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 35.6% and a 54.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intra-Cellular Therapies with a $29.50 average price target, representing a 35.1% upside. In a report issued on July 23, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.82 and a one-year low of $10.25. Currently, Intra-Cellular Therapies has an average volume of 353.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, I
